BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained an 'Outperform' rating on Centessa Pharmaceuticals and raised its price target from $20 to $35, indicating a positive outlook for the company's stock.
September 16, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has maintained an 'Outperform' rating on Centessa Pharmaceuticals and increased the price target from $20 to $35, suggesting a strong positive outlook for the stock.
The increase in the price target from $20 to $35 by BMO Capital indicates a strong positive sentiment towards Centessa Pharmaceuticals. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100